The steroid "dexamethasone" has been found to reduce the risk of death in seriously ill coronavirus patients by about a third, according to clinical trial results hailed on Tuesday as a "major breakthrough."
Researchers led by a team from the University of Oxford administered the inexpensive, widely available drug to more than 2,000 severely ill COVID-19 patients. Among those who could only breathe with the help of a ventilator, dexamethasone reduced deaths by 35%. It reduced deaths by about 20% among patients who were receiving oxygen only, according to preliminary results.
Dexamethasone is an anti-inflammatory drug normally used to treat a range of allergic reactions as well as rheumatoid arthritis and asthma.
According to The World Health Organisation (WHO) Daily doses of the drug could prevent one in eight ventilated patient deaths and save one out of every 25 patients requiring oxygen alone, the oxford team said.
The trial included a control group of 4,000 patients who did not receive the treatment.
"Dexamethasone is the first drug to be shown to improve survival in COVID-19. This is an extremely welcome result," said Peter Horby, professor of Emerging Infectious Diseases in the Nuffield Department of Medicine, University of Oxford. "Dexamethasone is inexpensive, on the shelf, and can be used immediately to save lives worldwide."
CBS News chief medical correspondent Dr. Jon LaPook explained that the drug helps by reducing dangerous inflammation that can overwhelm the body as a patient tries to fight off the virus.
"In the people who were intubated, who needed a breathing tube, their mortality went from 40% down to 28%. … And if they needed just oxygen, [mortality] went from 25% to 20%,"
Dr. Scott Krakower was not part of the clinical trial but received dexamethasone when he was battling the virus in April in New York City. For him, the drug was a game-changer.
"It was the first time in … almost a month that I stopped coughing," he told CBS News correspondent Manuel Bojorquez, describing it as "a mind-blowing moment."
Because dexamethasone is already FDA approved, Dr. Robert Glatter, an emergency physician at Lenox Hill Hospital in New York, was able to use it to treat Krakower. Glatter said he chose the drug due to its "potent anti-inflammatory properties."
The new research from the U.K. has not yet been published in a peer-reviewed medical journal, but experts are encouraged by the findings.
Britain's Health Secretary Matt Hancock said patients in that country would start to receive the drug immediately. He said the U.K. government had started stockpiling dexamethasone back in March after preliminary trials showed "early signs" of the drug's potential.
The trial results are particularly promising as around 40% of COVID-19 patients who require a ventilator end up dying, often because of the body's uncontrolled inflammatory response to the virus.
"This is a major breakthrough: dexamethasone is the first and only drug that has made a significant difference to patient mortality for COVID-19," said Nick Cammack, COVID-19 Therapeutics Accelerator Lead at the Wellcome Trust health charity. Potentially preventing one death in every eight ventilated patients would be remarkable.
No comments